Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:psychologist
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Rob_Burrow
gptkb:Doddie_Edwards |
| gptkbp:affects |
motor neurons
|
| gptkbp:caused_by |
progressive degeneration
|
| gptkbp:current_use |
gptkb:frontotemporal_dementia
pain spasticity |
| gptkbp:famous_person |
gptkb:Terry_Pratchett
gptkb:Stephen_Hawking gptkb:Morrissey gptkb:Lou_Gehrig gptkb:David_Niven |
| gptkbp:genetic_diversity |
gptkb:TARDBP
gptkb:C9orf72 FUS SO D1 |
| gptkbp:historical_figure |
awareness campaigns
advocacy for research funding |
| https://www.w3.org/2000/01/rdf-schema#label |
Motor Neurone Disease
|
| gptkbp:public_awareness |
gptkb:Motor_Neurone_Disease_Association_(MNDA)
gptkb:June gptkb:ALS_Association |
| gptkbp:research |
environmental factors
genetic factors ongoing studies |
| gptkbp:social_responsibility |
clinical examination
nerve conduction studies more common in men electromyography (EMG) variable progression affects 2 per 100,000 people average survival 3-5 years peak onset age 55-75 |
| gptkbp:symptoms |
difficulty speaking
respiratory problems muscle weakness difficulty swallowing muscle atrophy |
| gptkbp:treatment |
gptkb:Edaravone
gptkb:Riluzole medications physical therapy supportive care speech therapy |
| gptkbp:type_of |
Amyotrophic lateral sclerosis (ALS)
Bulbar onset ALS Primary lateral sclerosis (PLS) Progressive muscular atrophy (PMA) |